The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer

Cancer Research

Volumn 65, Issue 21, 2005, Pages 9906-9913

  Zhoul, Jian ^a   Hernandez, Gina ^a   Tu, Szu Wei ^a   Huang, Chien Ling ^b   Tseng, Ching Ping ^b   Hsieh, Jer Tsong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DIFFERENTIALLY EXPRESSED IN OVARIAN CANCER 2 PROTEIN; DISABLED 2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL GROWTH; CELL LEVEL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DAB2 GENE; DOC 2 GENE; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; BINDING, COMPETITIVE; CELL GROWTH PROCESSES; DIHYDROTESTOSTERONE; EPITHELIUM; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PHOSPHOTRANSFERASES; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 27544435790     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1481     Document Type: Article

References (37)

1. Lee DK, Chang CJ. Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 2003;88:4043-54.
2. Heiniein CA, Chang CJ. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
3. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
4. Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem 2003;278: 6936-41.
5. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-17.
6. Migliaccio A, Castoria G, Di Domenico M, et al. Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol 2002;83:31-5.
7. Castoria G, Lombardi M, Barone MV, et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 2003;161:547-56.
8. Sun M, Yang L, Feldman RI, et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src. J Biol Chem 2003;278:42992-3000.
9. Mok SC, Chan WY, Wong KK, et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998;16:2381-7.
10. Schwahn DJ, Medina D. p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis. Oncogene 1998;17:1173-8.
11. Kleeff J, Huang Y, Mok SC, et al. Down-regulation of DOC-2 in colorectal cancer points to its role as a tumor suppressor in this malignancy. Dis Colon Rectum 2000; 45:1242-8.
12. Fulop V, Colitti CV, Genest D, et al. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 1998;17:419-24.
13. Tseng CP, Brent DE, Li YM, et al. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 1998;139:3542-53.
14. Fuzili Z, Sun W, Mittellstaedt S, et al. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999;18:3104-13.
15. Tseng CP, Brent DE, Pong RC, et al. The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer. J Biol Chem 1999;274:31981-6.
16. Wang Z, Tseng CP, Pong RC, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 2002;277:12622-31.
17. Xu XX Yi T, Tang B, et al. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998;16: 1561-9.
18. Zhou J, Hsieh JT. The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 2001;276:27793-8.
19. Peterziel H, Mink S, Schonert A, et al. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18:6322-9.
20. Cato AC, Nestl A, Mink S, et al. Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE 2002;138:RE9.
21. Riegman PH, Vlietstra RJ, van der Korput JA, et al. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-30.
22. Kasper S, Rennie PS, Bruchovsky N. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 1994;269:31763-9.
23. Tseng CP, Huang CL, Huang CH, et al. Disabled-2 small interfering RNA modulates cellular adhesive function and MAPK activity during megakaryocytic differentiation of K562 cells. FEBS Lett 2003;541:21-7.
24. Huang CL, Cheng JC, Liao CH, et al. Disabled-2 is a negative regulator of integrin aIIbb3-mediated fibrinogen adhesion and cell signaling. J Biol Chem 2004;279: 42279-89.
25. Weijerman PC, Konig JJ, Wong ST, et al. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994;54:5579-83.
26. Navone NM, Olive M, Ozen M, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997; 3:2493-500.
27. Gaughan L, Logan IR, Cook S, et al. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002;277:25904-13.
28. Fu M, Rao M, Wang C, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23:8563-75.
29. Nishida T, Yasuda H. PIAS1 and PIASxα function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J Biol Chem 2002;277:41311-7.
30. Slack JK, Adams RB, Rovin JD, et al. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001;20:1152-63.
31. Paronetto MP, Farini D, Sammarco I, et al. Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol 2004;164:1243-51.
32. Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, et al. A genome-wide survey of RAS transformation targets. Nat Genet 2000;24:144-52.
33. Viola MV Fromowitz F, Gravez S, et al. Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986; 314:133-7.
34. Sumiya H, Masai M, Akimoto S, et al. Histochemical examination of expression of ras p21 protein and R1881-binding protein in human prostatic cancers. Eur J Cancer 1990;26:786-9.
35. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990;50:6830-2.
36. Hocevar BA, Mou F, Rennolds JL. Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J 2003;22:3084-94.
37. Zhou J, Scholes J, Hsieh JT. Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev 2001;20:351-62.